Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence ESMO Calls for Cancer to Remain a Flagship Priority in the Next EU Budget MOST POPULAR Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Seven Centres to form new Cancer Research UK network January 24, 2022 New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... March 31, 2021 Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer May 15, 2019 Load more HOT NEWS Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T Cells Cure Probability Models for Evaluation of Patients with a Previous Cancer... Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway
